Difamilast is a phosphodiesterase-4 inhibitor used for the treatment of atopic dermatitis. Atopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions.
- Mechanism
- Curator reviewed · 6 references
Atopic dermatitis is a chronic inflammatory skin disorder characterized by pruritic eczema. Although the specific mechanism(s) by which difamilast exerts its therapeutic action is not well defined, it is known that difamilast exert therapeutic effects on atopic dermatitis by selectively inhibiting phosphodiesterase-4 (PDE4) which increases cyclic adenosine 3',5'-monophosphate (cAMP) concentration which then suppresses the production of inflammatory cytokines. Studies also demonstrate that difamilast has higher selectivity for the PDE4B subtype compared to the other PDE4 subtypes.
- Primary indication
- Difamilast is indicated for the topical treatment of adults and pediatric patients 2 years of age and older with mild to moderate atopic dermatitis.Curator reviewed · 1 structured indication
- Formula / weight
- C23H24F2N2O5 · 446.451 g/mol (avg)
- First approval
- United States, 2026
- Code names
- OPA-15406
- Brand names
Resolves to
VFBILHPIHUPBPZ-UHFFFAOYSA-NSMILESCCOC1=CC=CC=C1C(=O)NCC1=COC(=N1)C1=CC=C(OC(F)F)C(OC(C)C)=C1What you can answer from here — as of September 13, 2026
Which other approved drugs treat the same conditions as Difamilast, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account